Q32 Bio Inc (QTTB)
Score for how it compares with the broader market is near the top of its range; smart-money score is on the low side; and price trend score is on the low side.
QTTB scores higher than 65% of the 1,101 tickers we compare it with (Health Care).
As of 9 October 2026, Q32 Bio Inc (QTTB) scores 49 out of 100 on the Market Census six-factor composite, which puts it at the Average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 9 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.88× 30-day average
- 52-week range
- 1.91 – 23.57
- Market cap
- $313.77M
- Earnings date
- 5 Nov 2026
- Volume
- 854,875
- Avg. volume (30d)
- 976,777
- Open
- 8.12
- Previous close
- 8.09
- Day's range (regular session)
- 7.94 – 8.46
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.51
- P/E (TTM)
- 8.52
- EPS (TTM)
- 2.29
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
Premium data held for QTTB
- 6 SEC Form 4 insider transactions in the last 90 daysPremium
Counts of rows Market Census holds for QTTB. A dash in the factor table above means that factor has no data for this ticker — it is not a locked value. Compare plans
What the score says about QTTB right now
Q32 Bio Inc (QTTB) currently scores 49/100 on the Market Census six-factor composite, at the Average score level. QTTB is +3.09% on the day and +1.52% over five sessions as of the most recent tick. Average sits in the middle. The good and the bad in QTTB's data roughly balance out right now. QTTB's strongest factor is strength vs the market at 100/100 — a very strong read on how QTTB has done next to the wider market. It describes what has happened, not what happens next. The weakest factor is insider trades at 10/100 — a well below average read on insider buying and selling. Insider filings for QTTB lean toward selling; on a thinly filed name a few filings can set this reading.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See QTTB in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent QTTB news
Latest headlines that name Q32 Bio, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026Yahoo
- Q32 Bio Announces Additional 36-Week Results And Initial Findings From The 16-Week Off-Drug Period From Part B Of The SIGNAL-AA Phase 2A Clinical Trial Evaluating Bempikibart In Patients With Severe Or Very Severe AA; Clinically Meaningful Efficacy Data Observed On Primary And Key Secondary EndpointBenzinga
- Q32 Bio: Durable Hair Regrowth Remains The GoalSeekingAlpha
- Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026Yahoo
- Q32 Bio Presents Additional 36-Week Data From Its Part B Of SIGNAL-AA Phase 2a Clinical Study Of Bempikibart At European Academy Of Dermatology And Venereology CongressBenzinga
We hide 2 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to QTTB’s 49, all within 1 point.
Sorted by closeness to QTTB’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.